Ocugen Business Summary

Ocugen, Inc. (OCGN) is a clinical-stage biotechnology company that generates revenue primarily through strategic licensing agreements, collaborative research milestones, and government grants, as it has not yet commercialized its proprietary pipeline. The company’s operations are organized into four high-potential segments: a Modifier Gene Therapy Platform (targeting inherited retinal diseases), Novel Biologic Therapies for retinal diseases, a Regenerative Medicine Cell Therapy Platform, and an Inhaled Mucosal Vaccine Platform. Its flagship "one-to-many" approach utilizes nuclear hormone receptors to regulate gene networks, offering a gene-agnostic alternative to traditional mutation-specific therapies. Ocugen competes directly with biopharmaceutical leaders such as Apellis Pharmaceuticals, Astellas Pharma, and Moderna, positioning itself as a disruptive specialist in the ophthalmology and infectious disease sectors by targeting broad patient populations that currently lack curative options. The company was co-founded in 2013 by Dr. Shankar Musunuri and Dr. Uday B. Kompella, both of whom possess deep technical pedigrees in pharmaceutical sciences. Dr. Musunuri, the current Chairman and CEO, is a 30-year industry veteran who previously spent 15 years at Pfizer/Wyeth leading global operations for the blockbuster vaccine Prevnar 13. The executive team was further strengthened in February 2026 with the appointment of Rita Johnson-Greene as Chief Financial Officer, following her senior roles at the Alliance for Regenerative Medicine and Spark Therapeutics. Other key leadership includes Chief Scientific Officer Dr. Arun Upadhyay and Chief Medical Officer Dr. Huma Qamar. Ocugen maintains a robust governance structure with a board of directors including Blaise Coleman and Kirsten Castillo, supported by institutional investors such as State Street, Goldman Sachs, and BlackRock.